Feasibility, tolerability, and preliminary effectiveness of an accelerated bilateral intermittent theta-burst stimulation protocol in adults with posttraumatic stress disorder and comorbid depressive disorder following mild traumatic brain injury

Classified as probably not a substantial claim.

Clinical response was defined as either a ≥50% reduction from Baseline or an absolute decrease from Baseline of at least the instrument's minimum clinically important difference (MCID; 5 points for PHQ-9; 10 points for PCL-5 total; 4 points for GAD-7), whichever criterion was met.

“clinical response was defined as either a ≥ 50% reduction from Baseline or an absolute decrease from Baseline of at least the instrument's minimum clinically important difference (MciD; 5 points for PhQ-9; 10 points for Pcl-5 total; 4 points for GaD-7), whichever criterion was met (Bauer-staeb et al. 2021;Kounali et al. 2022;löwe et al. 2004)”

• cites Bauer-Staeb et al. 2021 sourcePartly supported

  The Discussion reports that English primary-care services use a 4-point GAD-7 change to capture improvement, but describes it as a reliable-change threshold, not a fixed MCID. The paper's MCID estimates vary with baseline severity; its Discussion reports average estimates of 3.7 points for PHQ-9 and 3.3 for GAD-7. It does not establish the cited 5-point PHQ-9 or 10-point PCL-5 thresholds, or define response as either a 50% reduction from baseline or an MCID decrease. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Kounali et al. 2022 sourceDisputed

  The Results (ROC analysis, Table 5; page unavailable) give improvement thresholds of about 2 points for PHQ-9 and 1–2 points for GAD-7, rather than the claimed MCIDs of 5 and 4 points. The Discussion (Implications; page unavailable) says roughly 20% change corresponded to an MCID at moderate and higher severity, not a general 50% response threshold. The paper does not assess PCL-5. (LLM, conf=0.87)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites Löwe et al. 2004Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

Reporting followed the STROBE recommendations for cohort studies.

“Reporting followed the strengthening the Reporting of Observational studies in epidemiology (stROBe) recommendations for cohort studies (von elm et al. 2007).”

• cites von Elm et al. 2007 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Clinically significant depressive and posttraumatic symptoms persist in a substantial proportion of patients well beyond the acute injury period and contribute to prolonged disability, occupational disruption, and elevated health care utilisation.

“longitudinal data from civilian cohorts, including the tRacK-tBi study, indicate that clinically significant depressive and posttraumatic symptoms persist in a substantial proportion of patients well beyond the acute injury period and contribute to prolonged disability, occupational disruption, and elevated health care utilisation”

• cites Stein et al. 2019 sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

Intermittent theta-burst stimulation (iTBS) is a validated, substantially abbreviated alternative that is noninferior to conventional 10-Hz rTMS for depression.

“intermittent theta-burst stimulation (itBs) is a validated, substantially abbreviated alternative that is noninferior to conventional 10-hz rtMs for depression”

• cites Blumberger et al. 2018 sourceNot checked — no full text of the source
• cites Kishi et al. 2024 sourceSupported
• cites Lefaucheur et al. 2020 sourcePartly supported

  Section 10.3 reports that iTBS sessions take about 3 minutes versus more than 20 minutes for standard rTMS, and describes a large study finding left-prefrontal iTBS noninferior to conventional high-frequency rTMS for depression. But the guidelines say the evidence for iTBS remained insufficient to make a recommendation, so calling it a validated alternative overstates their conclusion. The supplied passages have no page numbers. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Repetitive transcranial magnetic stimulation (rTMS) is an established treatment for major depressive disorder.

“Repetitive transcranial magnetic stimulation (rtMs) is an established treatment for major depressive disorder”

• cites Blumberger et al. 2018 sourceNot checked — no full text of the source
• cites Kishi et al. 2024 sourceSupported
• cites Lefaucheur et al. 2020 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

The PCL-5 has demonstrated strong psychometric performance in civilian and veteran samples.

“the PtsD checklist for DsM-5 (Pcl-5) was used to quantify overall posttraumatic symptom burden and symptom-cluster scores for cluster B (intrusion), cluster c (avoidance), cluster D (negative alterations in cognition and mood), and cluster e (hyperarousal/reactivity); the Pcl-5 has demonstrated strong psychometric performance in civilian and veteran samples (Blevins et al. 2015;Bovin et al. 2016;W”

• cites Blevins et al. 2015 sourceNot checked — no full text of the source
• cites Bovin et al. 2016 sourceNot checked — no full text of the source
• cites Weathers et al. 2018 sourcePartly supported

  The Method (Measures: Sample 1; page not available) says PCL-5 scores have excellent psychometric properties and reports an internal-consistency alpha of .93. The Results (Convergent and discriminant validity) also report a strong correlation with CAPS-5 in the veteran sample. Our copy does not explicitly establish psychometric performance in civilian samples; its separate discussion of the PCL-C is not evidence for that part of the PCL-5 claim. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The PHQ-9 has established psychometric properties and sensitivity to change in the general population and in TBI samples.

“the Patient health Questionnaire-9 (PhQ-9) was used to quantify depressive symptom severity; the instrument has established psychometric properties and sensitivity to change in the general population and in tBi samples (Fann et al. 2005;Kroenke et al. 2001;löwe et al. 2004).”

• cites Fann et al. 2005 sourceNot checked — no full text of the source
• cites Kroenke et al. 2001 sourcePartly supported

  The Discussion reports strong validity evidence for the PHQ-9 in primary-care and obstetrics–gynecology patients. It also says the study was cross-sectional and that longitudinal studies were needed to establish sensitivity to change. This paper does not establish those properties in the general population or TBI samples. (LLM, conf=0.91)

  Experimental — accuracy not yet measured
• cites Löwe et al. 2004Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

The present cohort required the co-occurrence of PTSD, depressive disorder, and TBI, whereas much of the published evidence derives from cohorts selected for a single psychiatric diagnosis or for military service.

“this cohort required the co-occurrence of PtsD, depressive disorder, and tBi, whereas much of the published evidence derives from cohorts selected for a single psychiatric diagnosis or for military service”

• cites Madore et al. 2022 sourcePartly supported

  The Methods (Referral and Treatment Information; page unavailable) describe a cohort of VA patients recommended to have an MDD diagnosis, with PTSD permitted but not required. This supports the cited paper as an example of evidence from a military-veteran cohort that did not require all three conditions. It does not establish that *much* of the published evidence uses such cohorts; the requirement for PTSD, depression, and TBI describes the citing authors’ own cohort, not this source’s. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites Oberman et al. 2020 sourcePartly supported

  The Results sections on depressive and PTSD symptoms describe trials focused on one primary outcome and trials involving service members or veterans, supporting the broad contrast with the citing authors’ cohort. The paper does not establish that those cohorts were selected for a single psychiatric diagnosis; a primary outcome is not necessarily an enrollment criterion. The citing authors’ own cohort requirements are not attributed to this source. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites Petrosino et al. 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Depression and PTSD-the two domains for which TMS and theta-burst stimulation are most extensively supported-improved significantly at both post-treatment and follow-up.

“Depression and PtsD-the two domains for which tMs and theta-burst stimulation are most extensively supported (Blumberger et al. 2018;cole et al. 2022;Kishi et al. 2024;Petrosino et al. 2020;Philip et al. 2019)-improved significantly at both post-treatment and follow-up.”

• cites Blumberger et al. 2018 sourceNot checked — no full text of the source
• cites Cole et al. 2022 sourceNot checked — no full text of the source
• cites Kishi et al. 2024 sourcePartly supported

  The Introduction (page unavailable) says rTMS is recommended for treatment-resistant depression and that iTBS is approved for depression; the Results report improved depression outcomes with some TBS protocols. The paper does not address PTSD or compare which clinical domains have the most extensive support. The citation is attached to that background characterization, not to the citing authors’ post-treatment and follow-up results. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

May combine two claims.

The protocol was bilateral and accelerated, combining two design features that are individually supported but less commonly reported in combination.

“the protocol was bilateral and accelerated, combining two design features that are individually supported but less commonly reported in combination”

• cites Cole et al. 2022 sourceNot checked — no full text of the source
• cites Vaithianathan et al. 2022 sourcePartly supported

  The Introduction and Methods describe a bilateral protocol, and the Discussion says studies using bilateral TBS were scarce. But the Methods report 19–30 sessions over 4–6 weeks, not an accelerated schedule. The paper therefore does not support the claim that this protocol combined bilateral and accelerated delivery. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

The present estimate (exact 95% CI upper bound 5.6%) is consistent with the broader safety profile of iTBS established in large multicentre trials including THREE-D, and with emerging bilateral accelerated reports in trauma-related populations.

“the present estimate (exact 95% ci upper bound 5.6%) is consistent with the broader safety profile of itBs established in large multicentre trials including thRee-D (Blumberger et al. 2018), and with emerging bilateral accelerated reports in trauma-related populations (chang et al. 2023;Vaithianathan et al. 2022).”

• cites Blumberger et al. 2018 sourceNot checked — no full text of the source
• cites Chang et al. 2023 sourceSupported
• cites Vaithianathan et al. 2022 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

This cluster-specific pattern is consistent with neurobiological models implicating prefrontal-limbic regulation of arousal as a proximal mechanism of TMS effects in trauma-related populations, although the limited number of courses contributing to each cluster-level comparison (n ≈ 28 at Follow-up) reduces the precision of these estimates and warrants cautious interpretation.

“this cluster-specific pattern is consistent with neurobiological models implicating prefrontal-limbic regulation of arousal as a proximal mechanism of tMs effects in trauma-related populations, although the limited number of courses contributing to each cluster-level comparison (n ≈ 28 at Follow-up) reduces the precision of these estimates and warrants cautious interpretation (Petrosino et al. 202”

• cites Petrosino et al. 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Philip et al. 2019 sourcePartly supported

  Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Forty-seven of 59 courses with available data (79.7%) had no documented prior TBI.

“Forty-seven of 59 courses with available data (79.7%) had no documented prior tBi.”

May combine two claims.

Courses lacking a Post-treatment assessment had higher baseline severity than those with one on PHQ-9 (17.2 vs 12.9; p = .011), PCL-5 total (50.5 vs 39.9; p = .025), and GAD-7 (15.3 vs 11.7; p = .017), but not PSS (p = .33).

“whereas courses lacking a Post-treatment assessment had higher baseline severity than those with one on PhQ-9 (17.2 vs 12.9; p = .011),Pcl-5 total (50.5 vs 39.9; p = .025),and GaD-7 (15.3 vs 11.7; p = .017),but not Pss (p = .33)”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Motor vehicle collision was the predominant mechanism of injury (52 of 64 courses, 81.3%), followed by fall (8 of 64, 12.5%), and assault (1 of 64, 1.6%); three courses (4.7%) did not have a documented external precipitating injury.

“Motor vehicle collision was the predominant mechanism of injury (52 of 64 courses, 81.3%), followed by fall (8 of 64, 12.5%), and assault (1 of 64, 1.6%); three courses (4.7%) did not have a documented external precipitating injury.”

May combine two claims.

Fifty-four of 64 courses (84.4%; exact 95% CI, 73.1-92.2) completed the prespecified 80-session protocol, and one additional course received 90 sessions (an intentional extension documented in the clinical record).

“Fifty-four of 64 courses (84.4%; exact 95% ci, 73.1-92.2) completed the prespecified 80-session protocol, and one additional course received 90 sessions (an intentional extension documented in the clinical record).”

May combine two claims.

The remaining 9 courses (14.1%) received a shortened dose, with the distribution consisting of 10 sessions (n = 1), 20 sessions (n = 3), 40 sessions (n = 3), 48 sessions (n = 1), and 60 sessions (n = 1); in each case the clinical record documented early termination for logistical reasons rather than intolerance or adverse events.

“the remaining 9 courses (14.1%) received a shortened dose, with the distribution consisting of 10 sessions (n = 1), 20 sessions (n = 3), 40 sessions (n = 3), 48 sessions (n = 1), and 60 sessions (n = 1); in each case the clinical record documented early termination for logistical reasons rather than intolerance or adverse events.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

32 of 64 courses (50.0%) were delivered to female patients; at the patient level, 29 of 55 patients (52.7%) were female.

“32 of 64 courses (50.0%) were delivered to female patients; at the patient level, 29 of 55 patients (52.7%) were female.”

May combine two claims.

TBI severity was classified as mild in 63 of 64 courses (98.4%); one course was delivered to a patient whose injury did not meet diagnostic criteria for TBI but who was retained in the clinical pathway because of concordant clinical features.

“tBi severity was classified as mild in 63 of 64 courses (98.4%); one course was delivered to a patient whose injury did not meet diagnostic criteria for tBi but who was retained in the clinical pathway because of concordant clinical features.”

• AssumptionRests on an assumption: Clinical diagnoses recorded in the chart accurately identify PTSD, depressive disorder, and TBI.

May combine two claims.

No reviewed record documented seizure, syncope, persistent headache requiring medical evaluation, or site-specific adverse effects.

“no reviewed record documented seizure, syncope, persistent headache requiring medical evaluation, or site-specific adverse effects.”

• AssumptionRests on an assumption: The routine clinical documentation of adverse events captures all treatment-emergent adverse events relevant to tolerability.

May combine two claims.

Cluster D (negative alterations in cognition and mood) showed a numeric reduction at Follow-up, mean change -1.93 (dz = -0.31; p = .12), not reaching conventional significance at Follow-up but significant at Post-treatment.

“cluster D (negative alterations in cognition and mood), -1.93 (dz = -0.31;p = .12;numeric reduction not reaching the conventional significance threshold at Follow-up but significant at Post-treatment)”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

Probably not a substantial claim: may not pass S3 (load-bearing).

Mean age at injury was 36.7 years (SD 11.4; range 18-69).

“the mean age at injury was 36.7 years (sD, 11.4; range, 18-69)”

May combine two claims.

Baseline questionnaires were available for 63 of 64 courses, Post-treatment questionnaires for 39 (60.9%), and Follow-up questionnaires for 28 (43.8%).

“Baseline questionnaires were available for 63 of 64 courses, Post-treatment questionnaires for 39 (60.9%), and Follow-up questionnaires for 28 (43.8%)”

May combine two claims.

Sixty-four consecutive accelerated bilateral iTBS courses were delivered to 55 unique adults (nine patients received two or more separate courses) and met inclusion criteria.

“sixty-four consecutive accelerated bilateral itBs courses were delivered to 55 unique adults (nine patients received two or more separate courses during the study window) and met inclusion criteria.”

• AssumptionRests on an assumption: Clinical diagnoses recorded in the chart accurately identify PTSD, depressive disorder, and TBI.

May combine two claims.

The median course duration was 3 calendar days (IQR, 3-3), consistent with the 4-day accelerated schedule.

“the median course duration was 3 calendar days (interquartile range [iQR], 3-3), consistent with the 4-day accelerated schedule.”

May combine two claims.

Both the structured tolerability field and the free-text description were negative in all cases.

“Both the structured tolerability field and the free-text description were negative in all cases.”

• AssumptionRests on an assumption: The routine clinical documentation of adverse events captures all treatment-emergent adverse events relevant to tolerability.

May combine two claims.

Nonadherence was attributable to logistical rather than clinical causes, and all courses that began treatment received the intended 20 sessions per day.

“Nonadherence was attributable to logistical rather than clinical causes, and all courses that began treatment received the intended 20 sessions per day.”

May combine two claims.

At Follow-up, overall clinical improvement was 42.9% for PHQ-9, 50.0% for PCL-5 total, and 44.4% for GAD-7, exceeding the corresponding Post-treatment proportions (30.8%, 31.6%, and 32.4%, respectively).

“at Follow-up, overall clinical improvement was 42.9% for PhQ-9, 50.0% for Pcl-5 total, and 44.4% for GaD-7, exceeding the corresponding Post-treatment proportions (30.8%, 31.6%, and 32.4%, respectively).”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

May combine two claims.

Among the 21 courses with paired PHQ-9 data at both time points, 3 (14.3%) met the overall criterion at Post-treatment and sustained it at Follow-up, 2 (9.5%) met the criterion at Post-treatment but not at Follow-up, 6 (28.6%) met the criterion at Follow-up without having met it at Post-treatment (delayed response), and 10 (47.6%) met the criterion at neither time point.

“among the 21 courses with paired PhQ-9 data at both time points, 3 (14.3%)met the overall criterion at Post-treatment and sustained it at Follow-up, 2 (9.5%) met the criterion at Post-treatment but not at Follow-up, 6 (28.6%) met the criterion at Follow-up without having met it at Post-treatment (delayed response), and 10 (47.6%) met the criterion at neither time point.”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

Probably not a substantial claim: may not pass S3 (load-bearing).

The median follow-up interval was 39 days (IQR, 33-48).

“Median follow-up interval, d (IQr) | 39 (33-48)”

May combine two claims.

Among the 20 courses with paired PCL-5 total data, 4 sustained (20.0%), 0 not maintained (0.0%), 4 delayed (20.0%), and 12 no response at either time point (60.0%); no PCL-5 responder present at Post-treatment failed to maintain response at Follow-up (maintenance rate, 4 of 4, 100%).

“among the 20 courses with paired Pcl-5 total data, the corresponding figures were 4 sustained (20.0%), 0 not maintained (0.0%), 4 delayed (20.0%), and 12 no response at either time point (60.0%);notably, no Pcl-5 responder present at Post-treatment failed to maintain response at Follow-up (maintenance rate, 4 of 4, 100%).”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

May combine two claims.

The PSS showed a similar pattern, with a nonsignificant immediate post-treatment change but a medium-sized and significant reduction at follow-up.

“the Pss showed a similar pattern, with a nonsignificant immediate post-treatment change but a medium-sized and significant reduction at follow-up.”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

May combine two claims.

Among the 20 courses with paired GAD-7 data, 3 sustained (15.0%), 3 not maintained (15.0%), 4 delayed (20.0%), and 10 no response at either time point (50.0%).

“among the 20 courses with paired GaD-7 data, the corresponding figures were 3 sustained (15.0%), 3 not maintained (15.0%), 4 delayed (20.0%), and 10 no response at either time point (50.0%).”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

May combine two claims.

Follow-up assessments were available for 28 of 64 courses (43.8%), creating potential follow-up bias.

“follow-up assessments were available for 28 of 64 courses (43.8%), creating potential follow-up bias”

May combine two claims.

Within the PCL-5, all four symptom clusters improved, with the largest standardised effect in cluster E (hyperarousal/reactivity).

“Within the Pcl-5, all four symptom clusters improved, with the largest standardised effect in cluster e (hyperarousal/reactivity).”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

May combine two claims.

iTBS is a non-invasive, non-systemic intervention that avoids the systemic drug exposure, polypharmacy, and cognitive side effects that frequently limit pharmacotherapy after TBI.

“as a non-invasive, non-systemic intervention it avoids the systemic drug exposure, polypharmacy, and cognitive side effects that frequently limit pharmacotherapy after tBi”

Probably not a substantial claim: may not pass S3 (load-bearing).

The PSS quantifies the extent to which situations in the patient's life were appraised as stressful over the preceding month.

“the 10-item Perceived stress scale (Pss) was used to quantify the extent to which situations in the patient's life were appraised as stressful over the preceding month (cohen et al. 1983).”

• cites Cohen et al. 1983 sourceNot checked — no full text of the source

May combine two claims.

The largest cluster-level effect was observed in cluster E, consistent with previous reports implicating hyperarousal as a proximal target of prefrontal TMS in trauma-related populations.

“the largest cluster-level effect was observed in cluster e, consistent with previous reports implicating hyperarousal as a proximal target of prefrontal tMs in trauma-related populations.”

Classified as probably not a substantial claim. May combine two claims.

Follow-up assessments were those obtained ≥28 days after the last treatment day and prior to the start of any subsequent TMS course.

“Follow-up assessments were those obtained ≥28 days after the last treatment day and prior to the start of any subsequent tMs course.”

Classified as probably not a substantial claim.

Remission rates were expressed relative to an at-risk denominator comprising paired courses whose Baseline score was at or above the cut-off.

“remission rates were expressed relative to an at-risk denominator comprising paired courses whose Baseline score was at or above the cut-off, because courses already below the cut-off at Baseline cannot experience the transition.”

Probably not a substantial claim: may not pass S3 (load-bearing).

When multiple eligible assessments existed, the earliest qualifying assessment was used to reduce selection bias.

“When multiple eligible assessments existed, the earliest qualifying assessment was used to reduce selection bias.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Because validated dichotomous cut-offs are not established for the Perceived Stress Scale, categorical clinical outcomes were not computed for PSS and were restricted to PHQ-9, PCL-5 total, and GAD-7.

“Because validated dichotomous cut-offs are not established for the Perceived stress scale, categorical clinical outcomes were not computed for Pss and were restricted to PhQ-9, Pcl-5 total, and GaD-7.”

Classified as probably not a substantial claim.

Post-treatment assessments were those obtained between the final treatment day and 27 days thereafter.

“Post-treatment assessments were those obtained between the final treatment day and 27 days thereafter, capturing the immediate post-course evaluation.”

Classified as probably not a substantial claim.

Analyses of within-patient symptom change were conducted among patients with the relevant paired assessments available.

“analyses of within-patient symptom change were conducted among patients with the relevant paired assessments available.”

Classified as probably not a substantial claim. May combine two claims.

Before efficacy can be adjudicated in controlled trials, two prerequisites must be addressed: whether such an intensive protocol is feasible to deliver in a community outpatient setting, and whether it is tolerated by patients whose comorbid neurologic and psychiatric burden may increase susceptibility to stimulation-related side effects.

“Before efficacy can be adjudicated in controlled trials, two prerequisites must be addressed: whether such an intensive protocol is feasible to deliver in a community outpatient setting, and whether it is tolerated by patients whose comorbid neurologic and psychiatric burden may increase susceptibility to stimulation-related side effects.”

May combine two claims.

More severely symptomatic courses were less likely to have an immediate Post-treatment questionnaire while availability of the longer-term Follow-up assessment was unrelated to baseline severity.

“indicating that more severely symptomatic courses were less likely to have an immediate Post-treatment questionnaire while availability of the longer-term Follow-up assessment was unrelated to baseline severity”

Probably not a substantial claim: may not pass S3 (load-bearing).

A total score ≥33 on the PCL-5 is commonly used as a screening threshold suggestive of probable PTSD.

“a total score ≥33 is commonly used as a screening threshold suggestive of probable PtsD (U.s.Department of Veterans affairs, National center for PtsD, 2024).”

• cites U.S. Department of Veterans Affairs, National Center for PTSD, 2024Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

Feasibility was operationalised a priori as the proportion of courses that reached the prespecified treatment dose of ≥80 sessions, together with adherence to the 20-session-per-day schedule.

“Feasibility was operationalised a priori as the proportion of courses that reached the prespecified treatment dose of ≥80 sessions, together with adherence to the 20-session-per-day schedule.”

Classified as probably not a substantial claim.

Inclusion required established clinical diagnoses of PTSD, depressive disorder, and TBI recorded prior to TMS initiation.

“inclusion required established clinical diagnoses of PtsD, depressive disorder, and tBi recorded prior to tMs initiation”

• AssumptionRests on an assumption: Clinical diagnoses recorded in the chart accurately identify PTSD, depressive disorder, and TBI.

Classified as probably not a substantial claim.

Symptomatic remission was defined as a transition from a Baseline score at or above the validated clinical cut-off to a current score below the cut-off (PHQ-9 < 10, PCL-5 total <33, GAD-7 < 10).

“symptomatic remission was defined as a transition from a Baseline score at or above the validated clinical cut-off to a current score below the cut-off (PhQ-9 < 10, Pcl-5 total <33, GaD-7 < 10)”

Classified as probably not a substantial claim. May combine two claims.

Within-patient change in continuous symptom scores was analysed with paired t tests; the nonparametric Wilcoxon signed-rank test was reported as a sensitivity analysis.

“Within-patient change in continuous symptom scores was analysed with paired t tests; the nonparametric Wilcoxon signed-rank test was reported as a sensitivity analysis given the potential for non-normality in clinical score distributions.”

Probably not a substantial claim: may not pass S4 (based).

iTBS directly engages the dorsolateral prefrontal cortex and connected prefrontal-limbic circuitry implicated in the dysregulation of mood, arousal, and executive control that is common after brain injury.

“it directly engages the dorsolateral prefrontal cortex and connected prefrontal-limbic circuitry implicated in the dysregulation of mood, arousal, and executive control that is common after brain injury”

Probably not a substantial claim: may not pass S4 (based).

The established safety record of accelerated and theta-burst protocols mitigates the theoretical concern of seizure with intensive stimulation.

“and the established safety record of accelerated and theta-burst protocols mitigates the theoretical concern of seizure with intensive stimulation.”

Classified as probably not a substantial claim. May combine two claims.

Baseline symptom severity was compared between courses with and without an available Post-treatment assessment, and between courses with and without an available Follow-up assessment, using Welch t tests with Mann-Whitney U tests as a sensitivity analysis.

“to assess whether the courses contributing paired outcome data were representative of the full cohort, baseline symptom severity was compared between courses with and without an available Post-treatment assessment, and between courses with and without an available Follow-up assessment, using Welch t tests with Mann-Whitney U tests as a sensitivity analysis.”

Classified as probably not a substantial claim.

Two-sided P values <.05 were considered statistically significant.

“two-sided P values <.05 were considered statistically significant.”

Classified as probably not a substantial claim.

Tolerability was operationalised as the proportion of courses in which treatment-emergent adverse events were documented during routine clinical monitoring.

“tolerability was operationalised as the proportion of courses in which treatment-emergent adverse events were documented during routine clinical monitoring.”

May combine two claims.

Accelerated multi-session-per-day iTBS protocols have demonstrated safety and, in recent controlled trials such as SAINT, rapid antidepressant effects.

“with demonstrated safety and, in recent controlled trials such as saiNt, rapid antidepressant effects”

• cites Cole et al. 2022 sourceNot checked — no full text of the source

Classified as probably not a substantial claim. May combine two claims.

Because all outcomes were prespecified with a hierarchical primary/secondary/tertiary structure, no formal correction for multiple comparisons was applied; exploratory findings are interpreted accordingly.

“Because all outcomes were prespecified with a hierarchical primary/secondary/tertiary structure, no formal correction for multiple comparisons was applied; exploratory findings are interpreted accordingly.”

Classified as probably not a substantial claim.

All treatment courses, regardless of the number of sessions completed, were retained for feasibility and tolerability analyses to avoid completer bias.

“all treatment courses, regardless of the number of sessions completed, were retained for feasibility and tolerability analyses to avoid completer bias”

Probably not a substantial claim: may not pass S3 (load-bearing).

All analyses were performed in Python 3.10 using the pandas and SciPy libraries.

“all analyses were performed in Python 3.10 using the pandas and sciPy libraries.”

Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

Accelerated delivery carries particular appeal in TBI populations, in whom cognitive, occupational, and geographic barriers can limit adherence to prolonged daily treatment courses.

“accelerated delivery carries particular appeal in tBi populations, in whom cognitive, occupational, and geographic barriers can limit adherence to prolonged daily treatment courses.”

Classified as probably not a substantial claim.

All consecutive TMS treatment courses labelled under the PTSD + Depression clinical pathway between clinic inception and the data-lock date were included.

“all consecutive tMs treatment courses labelled under the PtsD + Depression clinical pathway between clinic inception and the data-lock date were included.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The GAD-7 has established reliability, validity, and sensitivity to change.

“the Generalised anxiety Disorder-7 (GaD-7) was used to quantify anxiety symptom severity, with established reliability, validity, and sensitivity to change (spitzer et al. 2006).”

• cites Spitzer et al. 2006 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Three categorical clinical outcomes were prespecified for each instrument: clinical response, symptomatic remission, and overall clinical improvement.

“three categorical clinical outcomes were prespecified for each instrument: clinical response, symptomatic remission, and overall clinical improvement.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Diagnoses were clinical rather than derived from structured research interviews.

“diagnoses were clinical rather than derived from structured research interviews.”

• AssumptionRests on an assumption: Clinical diagnoses recorded in the chart accurately identify PTSD, depressive disorder, and TBI.

Classified as probably not a substantial claim.

Baseline was defined as the most recent assessment obtained within 30 days prior to or on the first day of treatment.

“Baseline was defined as the most recent assessment obtained within 30 days prior to or on the first day of treatment.”

Classified as probably not a substantial claim. May combine two claims.

Documentation followed the standard clinic protocol of explicit adverse-event screening at each treatment session and at the post-treatment visit; the electronic record supplied both a structured yes/no field and a free-text description.

“Documentation followed the standard clinic protocol of explicit adverse-event screening at each treatment session and at the post-treatment visit; the electronic record supplied both a structured yes/no field and a free-text description.”

May combine two claims.

PTSD has most consistently been treated by targeting the right DLPFC, stimulation of which produces large reductions in posttraumatic symptoms together with concurrent improvement in anxiety and depression.

“PtsD, by contrast, has most consistently been treated by targeting the right DlPFc, stimulation of which produces large reductions in posttraumatic symptoms together with concurrent improvement in anxiety and depression”

• cites Berlim & Van den Eynde, 2014 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Overall clinical improvement was defined as the union of response and remission.

“Overall clinical improvement was defined as the union of response and remission.”

May combine two claims.

Paired analyses demonstrated consistent, clinically interpretable symptom reductions across the depressive, posttraumatic, anxiety, and perceived-stress domains, with standardised effect sizes in the medium-to-large range at short-term follow-up.

“Paired analyses demonstrated consistent, clinically interpretable symptom reductions across the depressive, posttraumatic, anxiety, and perceived-stress domains, with standardised effect sizes in the medium-to-large range at short-term follow-up.”

• AssumptionRests on an assumption: The observed symptom improvements are attributable to the iTBS protocol rather than to natural recovery, regression to the mean, or concurrent treatments.
• AssumptionRests on an assumption: The missing post-treatment assessments do not substantially bias the estimated within-patient symptom changes.

May combine two claims.

The present Follow-up window (median, 39 days) is sufficient to demonstrate short-term consolidation of benefit but not sufficient to adjudicate durability, relapse, or the time course of benefit.

“the Follow-up window (median, 39 days) is sufficient to detect short-term consolidation of benefit but is not sufficient to adjudicate durability”

• Also stated in: § Implications and future directions · boosted

  “the present Follow-up window (median, 39 days; iQR, 33-48) is sufficient to demonstrate that benefit continues to consolidate after the last treatment day, but is not sufficient to characterise durability, relapse, or the time course over which benefit either stabilises or attenuates”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Diagnoses were clinical; structured research interviews were not performed.

“diagnoses were clinical; structured research interviews were not performed”

May combine two claims.

Natural recovery, regression to the mean, concurrent psychotherapy or pharmacotherapy, and general effects of contact with a specialty service cannot be excluded as explanations for the observed changes.

“natural recovery, regression to the mean, concurrent psychotherapy or pharmacotherapy, and general effects of contact with a specialty service cannot be excluded”

May combine two claims.

This incremental Follow-up benefit across all three instruments is consistent with the dz trajectory described above for the continuous outcomes and suggests that the full clinical impact of an accelerated bilateral iTBS course is not captured at the immediate post-course assessment.

“this incremental Follow-up benefit across all three instruments is consistent with the dz trajectory described above for the continuous outcomes and suggests that the full clinical impact of an accelerated bilateral itBs course is not captured at the immediate post-course assessment.”

May combine two claims.

The tolerability estimate is derived from routine clinical documentation rather than a structured adverse-event instrument; mild transient side effects such as scalp discomfort or self-limited headaches may be underrepresented if not separately prompted.

“it is nonetheless derived from routine clinical documentation rather than a structured adverse-event instrument; mild transient side effects such as scalp discomfort or self-limited headaches may be underrepresented if not separately prompted.”

• AssumptionRests on an assumption: The routine clinical documentation of adverse events captures all treatment-emergent adverse events relevant to tolerability.

Probably not a substantial claim: may not pass S2 (checkable).

These findings provide a practical evidence base to inform the design of prospective controlled studies of accelerated bilateral iTBS in this clinically complex population.

“these findings provide a practical evidence base to inform the design of prospective controlled studies of accelerated bilateral itBs in this clinically complex population”

May combine two claims.

The cohort was predominantly composed of mild TBI after motor vehicle collision at a single site, which may limit generalisability to other TBI mechanisms, severities, and care settings.

“the cohort was predominantly composed of mild tBi after motor vehicle collision at a single site, which may limit generalisability to other tBi mechanisms, severities, and care settings”

Probably not a substantial claim: may not pass S3 (load-bearing).

Patients with incomplete follow-up could still differ from those with complete follow-up in ways not captured by the available covariates.

“patients with incomplete follow-up could still differ from those with complete follow-up in ways not captured by the available covariates”

May combine two claims.

The design was retrospective and uncontrolled, precluding causal inference.

“the design was retrospective and uncontrolled, precluding causal inference”

May combine two claims.

The GAD-7 trajectory was notable: the baseline-to-follow-up effect size (dz = -0.77) was the largest observed in this cohort, and exceeded the corresponding baseline-to-post-treatment effect, suggesting a possible progressive anxiolytic trajectory during the first month after stimulation.

“the GaD-7 trajectory was notable: the baseline-to-follow-up effect size (dz = -0.77)was the largest observed in this cohort, and exceeded the corresponding baseline-to-post-treatment effect, suggesting a possible progressive anxiolytic trajectory during the first month after stimulation.”

May combine two claims.

In this retrospective cohort of 64 consecutive accelerated bilateral iTBS courses delivered in a specialty outpatient pathway to adults with PTSD, depressive disorder, and predominantly mild TBI, the protocol was feasible to deliver as designed and was tolerated without chart-documented treatment-emergent adverse events.

“in this retrospective cohort of 64 consecutive accelerated bilateral itBs courses delivered in a specialty outpatient pathway to adults with PtsD, depressive disorder, and predominantly mild tBi, the protocol was feasible to deliver as designed and was tolerated without chart-documented treatment-emergent adverse events.”

• AssumptionRests on an assumption: The routine clinical documentation of adverse events captures all treatment-emergent adverse events relevant to tolerability.

Probably not a substantial claim: may not pass S2 (checkable).

The maintenance estimates derived here (e.g., 100% for PCL-5 total at a median of 39 days) should not be extrapolated to later time points without prospective 3-month and 6-month re-assessment.

“the maintenance estimates derived here (for example, 100% for Pcl-5 total at a median of 39 days) should not be extrapolated to later time points without prospective 3-month and 6-month re-assessment”

May combine two claims.

Across all three instruments, the overall rate at Follow-up exceeded the overall rate at Post-treatment, consistent with continued symptomatic consolidation during the first month after treatment.

“across all three instruments, the overall rate at Follow-up exceeded the overall rate at Post-treatment, consistent with continued symptomatic consolidation during the first month after treatment.”

May combine two claims.

Although the findings were consistent across domains and measures, the sample size is modest and comparative efficacy versus alternative TMS protocols cannot be adjudicated.

“although the findings were consistent across domains and measures, the sample size is modest and comparative efficacy versus alternative tMs protocols cannot be adjudicated”

Probably not a substantial claim: may not pass S3 (load-bearing).

The delayed-response signal may further expand with longer follow-up.

“the delayed-response signal described above may further expand with longer follow-up”

May combine two claims.

The protocol's compressed 4-day schedule shortens the treatment window from the conventional 4-6 weeks of daily rTMS to less than a week of intensive treatment, and in this cohort 85.9% of courses reached the prespecified 80-session dose.

“the protocol's compressed 4-day schedule shortens the treatment window from the conventional 4-6 weeks of daily rtMs to less than a week of intensive treatment, and in this cohort 85.9% of courses reached the prespecified 80-session dose.”

May combine two claims.

These findings support the feasibility and short-term tolerability of a 4-day accelerated bilateral iTBS protocol in a clinically complex PTSD, depression, and TBI population.

“these findings support the feasibility and short-term tolerability of a 4-day accelerated bilateral itBs protocol in a clinically complex PtsD, depression, and tBi population”

May combine two claims.

Tolerability was ascertained from clinical documentation rather than a structured patient-reported adverse-event instrument, which may underestimate low-grade side effects.

“tolerability was ascertained from clinical documentation rather than a structured patient-reported adverse-event instrument, which may underestimate low-grade side effects”

May combine two claims.

Together, these findings indicate that the clinical benefit of accelerated bilateral iTBS in this population may not be fully captured at the immediate post-treatment assessment and may continue to consolidate over the subsequent weeks.

“together, these findings indicate that the clinical benefit of accelerated bilateral itBs in this population may not be fully captured at the immediate post-treatment assessment and may continue to consolidate over the subsequent weeks.”

May combine two claims.

Both tertiary outcomes showed larger within-patient improvement at Follow-up than at the immediate Post-treatment assessment, suggesting a progressive rather than a peak-and-return trajectory within the short-term Follow-up window.

“Both tertiary outcomes showed larger within-patient improvement at Follow-up than at the immediate Post-treatment assessment, suggesting a progressive rather than a peak-and-return trajectory within the short-term Follow-up window.”

May combine two claims.

These findings extend the growing literature supporting accelerated iTBS as a practical, time-efficient alternative to conventional rTMS and provide an early signal that bilateral prefrontal delivery may be appropriate in a complex TBI-related clinical population.

“these findings extend the growing literature supporting accelerated itBs as a practical, time-efficient alternative to conventional rtMs and provide an early signal that bilateral prefrontal delivery may be appropriate in a complex tBi-related clinical population.”

• AssumptionRests on an assumption: The cohort is representative of the broader population of adults with PTSD, depressive disorder, and mild TBI receiving accelerated bilateral iTBS in routine outpatient care.

May combine two claims.

The cohort was drawn from routine outpatient care, which provides external validity for community delivery but limits the ability to enforce uniform follow-up timing or structured adverse-event capture.

“the cohort was drawn from routine outpatient care, which provides external validity for community delivery but limits the ability to enforce uniform follow-up timing or structured adverse-event capture”